PEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

361.96M

+14.72%

1.095

+12.86%

369.91M

+14.12%

1.089

+31.21%

387.40M

+14.12%

1.196

+39.07%

Estimates Revision

The market is revising Upward the revenue expectations for Penumbra, Inc. (PEN) for FY2025, with the revenue forecasts being adjusted by 0.94% over the past three months. During the same period, the stock price has changed by 21.85%.

Revenue Estimates for FY2025

Revise Upward

+0.94%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.57%

In Past 3 Month

Stock Price

Go Up

+21.85%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 307.92 USD with a low forecast of 266.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

266.00

Averages

307.92

High

355.00

Current: 0.000

Low

266.00

Averages

307.92

High

355.00

Evercore ISI

Vijay Kumar

Outperform

maintain

$286 -> $340

2026-01-05

New

Reason

Evercore ISI

Vijay Kumar

Price Target

$286 -> $340

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI analyst Vijay Kumar raised the firm's price target on Penumbra to $340 from $286 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

BofA

Buy

maintain

$320 -> $370

2026-01-05

New

Reason

BofA

Price Target

$320 -> $370

2026-01-05

New

maintain

Buy

Reason

BofA raised the firm's price target on Penumbra to $370 from $320 and keeps a Buy rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.

Truist

Buy

maintain

$312 -> $370

2025-12-18

Reason

Truist

Price Target

$312 -> $370

2025-12-18

maintain

Buy

Reason

Truist raised the firm's price target on Penumbra to $370 from $312 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

JPMorgan

Robbie Marcus

Neutral -> Overweight

upgrade

$275 -> $370

2025-12-18

Reason

JPMorgan

Robbie Marcus

Price Target

$275 -> $370

2025-12-18

upgrade

Neutral -> Overweight

Reason

JPMorgan analyst Robbie Marcus upgraded Penumbra to Overweight from Neutral with a price target of $370, up from $275. The firm says the ending headwinds and upcoming "major catalysts" have it bullish on the shares heading into 2026. JPMorgan sees a "strong likelihood" of positive estimate revisions to both Penumbra's sales and earnings in 2026. The company is e positioned to put up material upside to current Street numbers with the anniversary of China headwinds and a number of positive catalysts between Thunderbolt approval and multiple data readouts, the analyst tells investors in a research note.

Canaccord

Buy

maintain

$355 -> $359

2025-12-17

Reason

Canaccord

Price Target

$355 -> $359

2025-12-17

maintain

Buy

Reason

Canaccord raised the firm's price target on Penumbra to $359 from $355 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

RBC Capital

Shagun Singh

Outperform

maintain

$325 -> $355

2025-12-17

Reason

RBC Capital

Shagun Singh

Price Target

$325 -> $355

2025-12-17

maintain

Outperform

Reason

RBC Capital analyst Shagun Singh raised the firm's price target on Penumbra to $355 from $325 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that its U.S. VTE business continues to see strong traction and remains a notable driver in 2026. The firm expects U.S. VTE segment, with new launches and recently presented data, to contribute to positive uptake for this division.

Valuation Metrics

The current forward P/E ratio for Penumbra Inc (PEN.N) is 66.01, compared to its 5-year average forward P/E of 202.13. For a more detailed relative valuation and DCF analysis to assess Penumbra Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

202.13

Current PE

66.01

Overvalued PE

456.43

Undervalued PE

-52.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

91.77

Current EV/EBITDA

41.90

Overvalued EV/EBITDA

151.92

Undervalued EV/EBITDA

31.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.67

Current PS

7.96

Overvalued PS

11.17

Undervalued PS

6.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PEN News & Events

Events Timeline

No data

News

1.0

2025-12-29PRnewswire

Penumbra to Present at 44th Annual J.P. Morgan Healthcare Conference

4.0

2025-12-11Yahoo Finance

Penumbra Stock Increases Following Citigroup Upgrade

4.0

2025-12-11SeekingAlpha

Citi Lowers Intuitive Surgical Rating Ahead of 2026 MedTech Outlook

People Also Watch

Frequently Asked Questions

What is Penumbra Inc (PEN) stock price today?

The current price of PEN is 315.54 USD — it has decreased -0.19 % in the last trading day.

What is Penumbra Inc (PEN)'s business?

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

What is the price predicton of PEN Stock?

What is Penumbra Inc (PEN)'s revenue for the last quarter?

Penumbra Inc revenue for the last quarter amounts to 354.69M USD, increased 17.82 % YoY.

What is Penumbra Inc (PEN)'s earnings per share (EPS) for the last quarter?

Penumbra Inc. EPS for the last quarter amounts to 1.17 USD, increased 56.00 % YoY.

What changes have occurred in the market's expectations for Penumbra Inc (PEN)'s fundamentals?

How many employees does Penumbra Inc (PEN). have?

Penumbra Inc (PEN) has 4500 emplpoyees as of January 09 2026.

What is Penumbra Inc (PEN) market cap?

Today PEN has the market capitalization of 12.36B USD.